OBT at a glance

Pioneering an Innovative Approach for the Development of First-in-Class Cancer Therapies

Oxford BioTherapeutics is a clinical-stage oncology company, developing first-in-class antibody-based therapies to improve patient outcomes. Our proprietary, proteomic target discovery platform, OGAP®-Verify, specialises in identifying novel membrane-based protein targets.
This platform supports the development of antibody-drug conjugates (ADCs), chimeric antigen receptors (CAR-Ts), immuno-oncology antibodies (IOs), radiopharmaceutical and bispecific therapeutic modalities. We continuously enhance our OGAP®-Verify database to accurately represent patient tumours and the tumour microenvironment. Our fully integrated discovery and development capabilities span from target identification to IND-enabling studies.
View our Pipeline

OBT’s mission is to become a key player in the ADC and T-cell engagers (TCE) field, with a reputation for innovation, scientific excellence, and commitment to improving patient outcomes and bringing much-needed therapies to patients worldwide

Our Team

Our success at Oxford BioTherapeutics is driven by a team that expertly combines scientific rigour with medical expertise

Christian Rohlff, PhD

Chief Executive Officer, Oxford

Harald Haeske, MD, MBA

Chief Medical Officer, Oxford

Benjamin Thomas, PhD

SVP Operations, Oxford

Patrick Duxbury, BSc(Hons), CPE

General Counsel, Oxford

Andrew Dickinson, MSc

VP of Clinical Operations, Oxford

Stephen Blance, PhD CPA EPA

Director of Intellectual Property, Oxford

Stephanie Holmes, ACA

Finance Director​, Oxford

Belinda Cairns, PhD

Director of IHC Sciences, San Jose

Javier Morales, PhD

Associate Director Cell Biology, San Jose

Yu-Tzu Tai, PhD

Associate Director - ADC & Translational Research, San Jose

Madeline Tran

Associate Director of Protein Sciences, San Jose

Matthew Metzger

Program, Alliance and BD Manager, San Jose

Yu-Tzu Tai, PhD

Associate Director - ADC & Translational Research, San Jose

Dr. Tai joined Oxford BioTherapeutics in July 2022, bringing extensive cancer therapy research experience from new target identification to preclinical studies to successfully provide framework for clinical trials. She has contributed to FDA-approved treatments with small and biologic molecules, authored over 210 scientific publications, and spent 25 years at Dana Farber Cancer Institute in Boston. She is a long-term member of AACR and remains active on the Clinical Cancer Research editorial board. At Oxford BioTherapeutics, Dr. Tai leads internal ADC programs and preclinical studies for ongoing OBT076 trials while supporting external partnerships, all aimed at the development of novel immunotherapies for patients with unmet medical need. She earned her PhD in Environmental Toxicology from the University of Wisconsin-Madison.

Investors

Oxford BioTherapeutics is Supported by a Syndicate of Leading Specialist Investors

A major portion of the investment into our ADC, IO, CAR-T and bispecific pipeline comes from strategic alliances with leading companies in the oncology field.